Sponsor

Fundacion SEIMC-GESIDA

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Fundacion SEIMC-GESIDA appears in 24 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials24
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

24 shown
Effect of Extra Virgin Olive Oil Consumption on the Occurrence of Cardiovascular Events in Population Living With HIVNCT07761819 · lead sponsor · 2026-10-31
NOT_YET_RECRUITING
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral LoadNCT05898841 · lead sponsor · 2023-05-26
COMPLETED
Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric VulnerabilitiesNCT05549180 · lead sponsor · 2022-10-06
COMPLETED
Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED)NCT05405751 · lead sponsor · 2022-07-04
COMPLETED
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to LamivudineNCT04880785 · lead sponsor · 2021-07-28
COMPLETED
DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:NCT04884139 · lead sponsor · 2021-07-14
COMPLETED
A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV InfectionNCT04076423 · lead sponsor · 2019-10-10
COMPLETED
A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)NCT03685500 · lead sponsor · 2018-12-04
COMPLETED
A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017NCT03626467 · lead sponsor · 2018-10-15
COMPLETED
Spanish Cohort of Patients with HIV Infection Older Than 50 Years for the Study of Fragility and Physical FunctionNCT03558438 · lead sponsor · 2018-05-07
UNKNOWN
A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe ImmunosuppressionNCT03693508 · lead sponsor · 2018-04-13
COMPLETED
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM StudyNCT03067285 · lead sponsor · 2017-09-08
COMPLETED
Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical PracticeNCT03042390 · lead sponsor · 2016-12-23
COMPLETED
Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 InfectionNCT03158077 · lead sponsor · 2016-11-15
COMPLETED
Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected SubjectNCT02159599 · lead sponsor · 2014-07-01
COMPLETED
Observational, Retrospective, Multicenter Study to Describe the Reasons for the Change of the Regimen of Antiretroviral Therapy in HIV PatientsNCT02039921 · lead sponsor · 2013-10-01
COMPLETED
A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ PatientsNCT01946009 · lead sponsor · 2013-09-01
COMPLETED
Retrospective Study to Determine the Incidence of Bone Fractures in HIV-infected Patients in SpainNCT02045537 · lead sponsor · 2013-06-01
UNKNOWN
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance TherapyNCT01307488 · lead sponsor · 2011-09-01
COMPLETED
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With FosamprenavirNCT01222611 · lead sponsor · 2011-03-01
COMPLETED
Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABCNCT00865475 · lead sponsor · 2008-12-01
COMPLETED
Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With LipoatrophyNCT00865007 · lead sponsor · 2008-12-01
COMPLETED
Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/rNCT00866021 · lead sponsor · 2008-02-01
COMPLETED
The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWIDNCT02971488 · collaborator · 2017-01-15
COMPLETED

Drugs studied in this sponsor's trials

5 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Fundacion SEIMC-GESIDA as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
bictegravir 50 MG / emtricitabine 200 MG / tenofovir alafenamide 25 MG Oral Tablet [Biktarvy]1
dolutegravir 50 MG / lamivudine 300 MG Oral Tablet [Dovato]1
fosamprenavir1
lamivudine1
lopinavir / ritonavir1
bictegravir 50 MG / emtricitabine 200 MG / tenofovir alafenamide 25 MG Oral Tablet [Biktarvy] RxCUI 1999673 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dolutegravir 50 MG / lamivudine 300 MG Oral Tablet [Dovato] RxCUI 2122526 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial fosamprenavir RxCUI 358262 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial lamivudine RxCUI 68244 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial lopinavir / ritonavir RxCUI 284640 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor23
collaborator1
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.